So, talk with your doctor, discuss the options available to you, and decide on an appropriate course of action
GLP-1RAs reduce events linked to atherogenic cardiovascular disease (especially ischemic stroke) and also renal outcomes (FLOW trial with semaglutide), with a limited effect on heart failure
Despite their effectiveness, plateaus can still occur and slow or stop weight loss
prospective open-label study, the GLP-1 RA group (liraglutide, semaglutide) continued acetazolamide at a mean dose of approximately 1000 mg, with the option to taper if headaches improved [27]
For a given caloric intake, this could alter the nutrient load entering the portal circulation (143146)
Store lyophilized powder at 2-8C prior to reconstitution